Our Opinion

KemPharm, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products, services, research and therapies.

Supporting Evidence:

“We are pleased that KP511 continues to confirm our Ligand Activated Therapy (LAT) prodrug approach by delivering human pharmacokinetic data consistent with our preclinical animal model. The data from the Phase 1, proof-of-concept trial suggest that oral administration of KP511 in solution efficiently releases hydromorphone with a pharmacokinetic profile that is similar to Dilaudid Oral Liquid. This represents an important developmental milestone in the advancement of KP511 as an abuse-deterrent, ER pain therapeutic,” stated Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm. Read the following article

Company Description

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. Its portfolio of product addresses pain, attention-deficit or hyperactivity disorder, and central nervous system. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA. [Source: MarketWatch]

Company Website: http://www.kempharm.com